21Shares has filed an amended S-1/A registration statement for its proposed Injective ETF, with plans to list the product on Nasdaq under the ticker TINJ. The fund is designed to track the performance of the INJ token by using the FTSE Injective Index as its benchmark. The filing also says the fund may stake part of its INJ holdings when appropriate in order to earn staking rewards. The amendment relates to the initial application submitted in October 2025. The ETF has not been approved for listing at this stage, and its custody arrangement has yet to be finalized. The update was cited by Odaily, which referenced Crypto Briefing.
21Shares has filed an amended S-1/A registration statement for its planned Injective ETF, with the product set for a Nasdaq listing under the ticker TINJ.
Based on the filing, the fund would track the INJ token by using the FTSE Injective Index as its benchmark. And if conditions allow, it could also stake a portion of its INJ holdings to generate staking rewards.
This amendment ties back to the original application submitted in October 2025. The product still has not been approved for listing, and the custody setup is still waiting on final confirmation. The update was reported by Odaily, which cited Crypto Briefing.
This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan. Disclaimer:
The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.
Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.
